Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Melanoma and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MFI2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MFI2 ECD-Fc Fusion Protein (HEK293 expressed, native glycosylation, >95% purity, endotoxin <1EU/µg). Sequence verified. | View MFI2 Products |
| Gene Delivery | MFI2 Lentivirus Particles (full-length ORF, GPI-anchored expression, high titer) for stable cell line generation. | View MFI2 Products |
| Benchmark Ab | Anti-MFI2 Reference Antibody (recombinant positive control for binding and internalization assays). | View MFI2 Products |
| Validator | MFI2 siRNA Set for knockdown verification and genetic specificity controls. | View MFI2 Products |
| Related Target A | TFRC (Transferrin Receptor 1) — iron transport pathway partner, critical for cross-reactivity screening. | View TFRC Products |
| Related Target B | PMEL — synergistic target in melanoma progression and differentiation. | View PMEL Products |
| Related Target C | TF (Serotransferrin) — serum iron transporter; essential for off-target binding panels. | View TF Products |
| Related Target D | TFR2 (Transferrin Receptor 2) — liver iron sensor; pathway partner for combination studies. | View TFR2 Products |
| Related Target E | FTH1 (Ferritin Heavy Chain) — intracellular iron storage; downstream marker for iron deprivation assays. | View FTH1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Post-translational Modification (Glycosylation) Integrity | HEK293 expression ensures native glycosylation, correct epitope conformation. |
| ADC Internalization Assays | High purity (>95%) ECD-Fc fusions with endotoxin <1EU/µg for cell-based assays. pHrodo-based uptake quantification available with lentiviral cell lines. |
| GPI-Anchor Conformation vs Soluble Shedding | Dual format: purified ECD-Fc for SPR/BLI; lentivirus for cell surface GPI-expression (flow cytometry validation). |
| Serotransferrin (TF) Cross-Reactivity Risk | Strict sequence homology analysis >85% exclusion; ortholog panel (human/cyno/mouse) with mass spec verification. |
| Iron-Binding State Impact on Epitope | Theoretical apo- and holo-protein configurations (iron-saturated vs iron-free) for MOA-specific binding assays. |
| Lack of Specificity Controls | Validated siRNA and ORF rescue constructs included for genetic validation. |
| False Positives in Binding Assays | Sequence-verified antigens and benchmark antibodies ensure minimal background. |
Live MFI2/MELTF/CD228 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MFI2/MELTF/CD228 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and bispecific antibodies. Because MFI2 is highly expressed in melanoma and other solid tumors while having restricted normal tissue expression, it represents an ideal ADC target. As first-generation therapies reach the clinic, the next wave of R&D targets highly potent payload delivery and combination strategies to overcome tumor microenvironment resistance. The GPI-anchored nature of MFI2 also presents unique challenges for internalization and epitope accessibility, making high-quality reagents critical for assay development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Early-stage biotech | Melanoma, Solid Tumors | Internalization Assay (high-purity ECD-Fc) |
| Monoclonal Antibody | Academic/Translational | Metastatic Melanoma | Affinity Ranking (sequence-verified antigens) |
| Bispecific Antibody | Preclinical innovators | Solid Tumors | Heterodimer Validation (cross-reactive Abs) |
Functional Domains & Key Mutations (Fact Payload Integration)
MFI2 (MELTF) belongs to the transferrin family and contains two conserved transferrin-like domains: Transferrin-like 1 and Transferrin-like 2 (UniProt P08582). These domains mediate iron binding and cellular uptake. Clinically relevant single nucleotide polymorphisms (SNPs) include:
- rs2276790 (VAR_020413): a missense variant in the Transferrin-like 1 domain.
- rs17129219 (VAR_057304): a missense variant in the Transferrin-like 2 domain. Both mutations may influence protein conformation, iron affinity, and immunogenicity, underscoring the need for mutant protein reagents (available via TarMart's ECD-Fc mutant series).
Molecular Differentiation & Assay Strategy for Best-in-Class Drug Development
Developing a best-in-class MFI2 therapeutic requires addressing several molecular differentiation criteria:
- Affinity and Internalization Efficiency: ADC targets need moderate-high affinity with efficient receptor-mediated endocytosis. Too high affinity can cause binding site barrier in solid tumors. Recommended assays: SPR/BLI kinetic screening with high-purity ECD-Fc, and internalization assays using lentivirus-generated stable cell lines (e.g., pHrodo uptake).
- Safety and Cross-Reactivity: Avoid off-target binding to transferrin family members (TFRC, TF, TFR2). Recommended: cross-reactivity ELISA panel using ortholog proteins.
- Epitope and Glycosylation Integrity: Native glycosylation (HEK293-produced antigens) is essential to avoid false-positive clones. Use FACS binding assays with live cells expressing GPI-anchored MFI2.
- Iron-Binding State Impact: The iron-loaded vs iron-free conformational differences affect epitope availability. Use both apo- and holo-protein configurations in screening.
- Genetic Validation: Include siRNA knockdown and ORF rescue constructs to confirm target specificity.
TarMart's product line directly addresses these needs, offering HEK293-expressed ECD-Fc, lentiviral particles, benchmark antibodies, and validated siRNAs—all with documented quality control (>95% purity, low endotoxin).
Related Targets for Cross-Selling & Combination Research
- TFRC (Transferrin Receptor 1): Essential for cross-reactivity screening and as a baseline comparator for internalization kinetics.
- TF (Serotransferrin) & TFR2: Iron metabolism pathway partners; important for combination studies and off-target panels.
- PMEL & TYR (Tyrosinase): Melanoma-specific markers for multi-target diagnostic panels or bispecific antibody designs.
- FTH1 (Ferritin Heavy Chain): Downstream iron storage marker for assessing iron deprivation effects of MFI2-targeted therapies.
All related target reagents are available under the View XX Products catalog system.